Search

New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published today in the New England Journal of Medicine.

… Wednesday, June 2, 2021 New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD , and colleagues found that patients who received nivolumab (Opdivo®)  after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research

The MSK Therapeutics Accelerator is accepting applications to its 2026 Cohort Program from pharmaceutical and biotech companies eager to accelerate and de-risk the development of innovative therapeutics for people with cancer. Scheduled to begin in June, the 2026 Cohort Program will facilitate tailored mentorship with MSK faculty, while providing access to MSK’s drug development expertise, resources, and a pathway for future collaboration in the MSK Therapeutics Accelerator.

… Friday, February 6, 2026 The MSK Therapeutics Accelerator is accepting applications to its 2026 Cohort Program from pharmaceutical and biotech companies eager to accelerate and de-risk the development of innovative therapeutics for people with cancer. Scheduled to begin in June, the 2026 Cohort Program

During the height of the COVID-19 pandemic, when the constant sound of sirens filled the streets of New York City, Memorial Sloan Kettering Deputy Chief Nurse Kevin Browne found himself in a somewhat unfamiliar place: in the back of an ambulance headed to MSK—this time as a patient. 

… Friday, October 9, 2020 During the height of the COVID-19 pandemic, when the constant sound of sirens filled the streets of New York City and the surrounding communities, Memorial Sloan Kettering Deputy Chief Nurse Kevin Browne found himself in a somewhat unfamiliar place: in the back of an ambulance

In April 2022, the FDA approved the immunotherapy drug axicabtagene ciloleucel (Yescarta®) for the treatment of diffuse large B cell lymphoma earlier in the course of disease. Retired teacher and basketball coach Joe Crimi is one of the patients who benefited from this treatment.

… Thursday, May 5, 2022 When Joe Crimi found out that his lymphoma had returned after he’d been in remission for almost a year, he was “pretty depressed,” he remembers. His doctor at the hospital on Long Island where he’d received his initial treatment told him he would probably need a bone marrow transplant

Lung cancer has an uncanny ability to change its identity to resist drugs. Researchers are learning what drives these changes.

… Wednesday, July 7, 2021 When a person with lung cancer stops responding to a particular drug treatment, one possible reason is the cancer has morphed into a different subtype that is no longer sensitive to that drug. This phenomenon, known as lineage plasticity, is responsible for about 15% of cases

Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce The Washington Post has named Vinod Balachandran, MD, surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK, to the inaugural edition of the Post Next 50, a list of up-and-coming changemakers shaping society in 2025.

… Tuesday, February 11, 2025 Post Next Logo Courtesy of the Washington Post Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce The Washington Post has named  Vinod Balachandran, MD, surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK, to the inaugural edition

Learn how people with cancer can protect themselves against foodborne illness.

… Monday, May 23, 2022 Foodborne illness (also known as food poisoning) is a special concern for people with cancer. Their immune systems are weaker than those of the general public, which makes it harder to fight off dangerous pathogens in foods that are undercooked, past their expiration date, or improperly

Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2–6 in Chicago.

… Tuesday, May 30, 2023 Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2

Performers from Hamilton, Company, Harry Potter and the Cursed Child, Carmen Jones and more bring MSK patients’ stories to life on March 22 and 29.

… Tuesday, March 16, 2021 Summary Performers from Hamilton , Company , Harry Potter and the Cursed Child , Carmen Jones and more bring MSK patients’ stories to life on March 22 and 29. On Monday, March 22 at 6:30 p.m. ET, with an encore performance at 9:00 p.m. , Visible Ink will present Act One of its

Gerstner Sloan Kettering student research has been recognized with the Grayer Fellowships, the Catell Fellowship, the Olayan Fellowship, the Palestin Fellowship, and the Geoffrey Beene Graduate Student Fellowship.

… Friday, September 7, 2012 Grayer Fellows Third-year students Marta Kovatcheva and Yilong Zou have been named Grayer Fellows. The fellowships were established by Mr. and Mrs. Jonathan Grayer. Mr. Grayer is a member of the Gerstner Sloan Kettering Board of Trustees, the Memorial Sloan Kettering Cancer